Jennifer J. Rhodes - 06 Feb 2024 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
EVP, CHIEF LEGAL OFFICER, SEC
Signature
/s/ Jennifer J. Rhodes
Issuer symbol
ACAD
Transactions as of
06 Feb 2024
Net transactions value
$0
Form type
4
Filing time
08 Feb 2024, 17:09:17 UTC
Previous filing
04 Mar 2022
Next filing
26 Mar 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Stock Option (Right to Buy) Award $0 +126,589 $0.000000 126,589 06 Feb 2024 Common Stock 126,589 $25.74 Direct F1
transaction ACAD Restricted Stock Units Award $0 +25,889 $0.000000 25,889 06 Feb 2024 Common Stock 25,889 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the Stock Option will vest and become exercisable on February 6, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3 50% of the restricted stock units vest on February 6, 2026 and 25% vest on each of February 6, 2027 and February 6, 2028.